LEOPARD Prospective Validation Cohort 1

Inclusion Criteria: * Adult \[age 18;70\] patients listed for: * decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology (subset1) OR * other end-stage liver diseases requiring LT, listed under MELD offering schemes (subset 2), including notably but not exclusively cholestatic diseases, primary biliary cholangitis, primary sclerosing cholangitis (subset 2) OR * HCC as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis (subset 3). (HCC diagnosed on Barcelona/EASL criteria or histologically proven. HCC meeting or not Milan criteria, as per center practice.) * Patients registered on national waiting lists under the MELD offering schemes, regardless of extra MELD points are affected or not. * Patient (or trusted person, family member or close relation, if the patient is unable to express consent) who has been informed and signed the informed consent. * Patient affiliated with a health insurance scheme (beneficiary or entitled party). Exclusion Criteria: * Tumor vascular invasion (portal or hepatic veins) evidenced by imaging on pre transplantation work-up, including PVT stage 1 * Extra-hepatic metastasis of HCC, as assessed by sectional imaging, functional imaging (18 FDG PET CT/MRI) or histologically proven * Women who are pregnant or nursing * Patients who are under safeguard of justice or tutorship or curatorship * Patient on AME (state medical aid) * Participation in another trial including other studies proposed as part of the European LEOPARD project (cohort associated to WP1 \& WP5 ("LEOPARD TVDCS") or being in the exclusion period following previous interventional research involving the human person, if applicable